Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBS Oklahoma TB Testing Coverage Update | OpenPay…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - OklahomaPolicy CPCPLAB027

    Testing for Diagnosis of Active or Latent Tuberculosis

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLAB027 alerts

    Get alerted when Policy CPCPLAB027 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines BCBSOK reimbursement and coding stance for laboratory tests to diagnose or screen for active and latent tuberculosis, including restrictions and conditions for reimbursement for providers billing BCBSOK.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyTesting for Diagnosis of Active or Latent Tuberculosis
    Policy CodePolicy CPCPLAB027
    Change TypeCoding updates and NAAT/terminology revision
    Effective DateApr 24, 2026
    Last ReviewJan 7, 2026
    Next Review DateN/A
    Key ActionProviders must submit accurate documentation and use the updated procedure codes listed in the policy update history for reimbursement.
    SourceLink
    POLICY UPDATE CHANGES

    Added codes 87182 and 87183.

    Added codes 87564 and 0574U and removed codes 87149, 87550, 87555, 87560.

    Qualitative NAAT for Mycobacteria spp., M. tuberculosis, and M. avium complex was added and direct probe testing was removed.

    11distinct reimbursement provisions and exclusions listed
    30+procedure codes cited
    3most recent code additions
    4codes removed in prior update
    1.0document version

    Coverage Criteria for TB Testing

    TB testing coverage rules

    Reimbursable tests and conditions

    ALL of the following

    • ONE of

      • IGRA may be reimbursable to diagnose or screen for latent TB in individuals at risk for Mycobacterium tuberculosis (Mtb) infection or when screening is legally required.
      • For suspected TB infections, the following may be reimbursable: AFB smear/stain; culture and culture-based drug susceptibility testing of Mycobacteria spp.
      • Direct probe or amplified probe nucleic acid-based testing, including PCR, may be reimbursable for Mycobacteria spp, M. tuberculosis, and M. avium intracellulare (note: policy history replaces vendor-specific terminology with NAAT).
    • ALL of the following

      • ONE of

        • Prior treatment for tuberculosis.
        • Born in or lived ≥1 year in a foreign country with at least moderate TB incidence (≥20 per 100,000) or with high primary MDR-TB prevalence (≥2%).
        • Contact of an individual with multi-drug resistant (MDR) TB.
        • HIV infection.
    • ALL of the following

      • ONE of

        • Sputum cultures remain positive after 3 months of treatment.
        • Bacteriological reversion from negative to positive.
    • For individuals with pleural effusion, pericardial effusion, or ascites and suspected TB, measurement of cell counts, protein, glucose and lactate dehydrogenase (LDH) concentrations of cerebrospinal, pleural, peritoneal, pericardial, and other fluids may be reimbursable.

    Reimbursement criteria summary

    Reimbursement information and clinical criteria (as summarized in policy history):

    ALL of the following

    • AFB smear/stain, culture, and culture-based drug susceptibility testing are listed as reimbursable for suspected TB infections.
    • Qualitative nucleic acid amplification testing (NAAT) for Mycobacteria spp., M. tuberculosis, and M. avium complex was added to reimbursable tests; direct probe testing was removed as it is no longer available and vendor-specific references (eg, Hologic Amplified MTD) were replaced with NAAT terminology.
    • Molecular-based drug susceptibility testing may be reimbursable for AFB smear positive or NAAT positive patients when clinical risk factors are present (prior TB treatment; birth in or ≥1 year residence in country with moderate/high TB incidence; contact of an MDR-TB case; or HIV infection).
    • Policy code updates recorded in the history: added codes 87182, 87183 (01/07/2026) and previously added codes 87564, 0574U with removal of codes 87149, 87550, 87555, 87560 (09/26/2025).

    Procedure Codes and Coding Changes

    Potentially relevant procedure codesmixed
    81099
    82945
    83520
    83615
    84157
    84311
    86480
    86481
    87070
    87077
    1–10 of 33
    1/4
    Recent code additions and removalsmixed
    87182Added code (see policy history)
    87183Added code (see policy history)
    87564Added code (see policy history)
    0574UAdded code (see policy history)
    87149Removed code (see policy history)
    87550Removed code (see policy history)
    87555Removed code (see policy history)
    87560Removed code (see policy history)

    Provider Responsibilities and Update Actions

    Documentation Required

    Documentation and Claims Review — submit accurate documentation and respond to requests

    Providers are responsible for submission of accurate documentation of services performed and must code claims using valid HIPAA-approved code sets and industry standard coding guidelines. Claims are subject to code edit protocols and may be reviewed against plan coverage, provider contract language, medical policies, clinical payment and coding policies, and coding software logic; upon request, providers should submit any additional documentation to support the claim.

    • Submit accurate documentation of services performed.
    • Use valid code combinations from HIPAA-approved code sets and follow industry coding guidelines (CPT, HCPCS, ICD-10-CM/PCS, UB, NDC, CMS NCCI/CCI, etc.).
    • Be prepared for claim review against plan documents, provider contracts, medical/clinical payment and coding policies, and automated code edits.
    • Provide additional documentation promptly upon request.

    Definitions and Test Descriptions

    inv-07: IGRA — definition/coverage note for Interferon Gamma Release Assay.
    DefinitionInterferon gamma release assay (IGRA) to diagnose or screen for latent tuberculosis (TB) infection.
    Reimbursable useMay be reimbursable for individuals at risk for Mycobacterium tuberculosis (Mtb) infection or when screening is legally required.
    Not reimbursableNot reimbursable for individuals with active tuberculosis.
    Ordering noteIGRA is a screening test for latent TB and should not be used to diagnose active TB disease.
    inv-08: AFB smear / culture — definition/coverage note for Acid Fast Bacilli smear, culture, and susceptibility testing.
    DefinitionAcid fast bacilli (AFB) smear/stain, culture, and culture-based drug susceptibility testing of Mycobacteria spp.
    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyTesting for Diagnosis of Active or Latent Tuberculosis
    Policy CodePolicy CPCPLAB027
    Change TypeCoding updates and NAAT/terminology revision
    Effective DateApr 24, 2026
    Last ReviewJan 7, 2026
    Next Review DateN/A
    Key ActionProviders must submit accurate documentation and use the updated procedure codes listed in the policy update history for reimbursement.
    SourceLink
    On This Page
    Coverage Criteria for TB TestingProcedure Codes and Coding ChangesProvider Responsibilities and Update ActionsDefinitions and Test Descriptions
    Billing Rule

    Coding update actions — use updated CPT/HCPCS/Lab codes

    The policy history documents specific CPT/HCPCS/Lab code additions and removals; providers must use the updated codes when billing for TB-related tests per the policy update history.

    • Recent additions include codes 87182, 87183 (01/07/2026) and 87564, 0574U (09/26/2025).
    • Codes removed in prior updates include 87149, 87550, 87555, and 87560 (09/26/2025).
    • Refer to the Policy Update History when selecting procedure codes to ensure reimbursement eligibility.
    Reimbursable useMay be reimbursable for all suspected TB infections to detect Mycobacteria spp.
    Drug susceptibilityCulture-based drug susceptibility testing may be reimbursable when clinically indicated (see molecular DST criteria).
    Clinical contextRepeat drug susceptibility testing may be reimbursable when sputum cultures remain positive after 3 months of treatment or with bacteriological reversion from negative to positive.
    inv-09: Nucleic acid-based testing (NAAT/PCR) — definition/coverage note for direct probe/amplified probe/NAAT methods.
    DefinitionDirect probe or amplified probe nucleic acid-based testing, including PCR, for detection of Mycobacteria spp., M. tuberculosis, and M. avium intracellulare.
    Reimbursable useMay be reimbursable for Mycobacteria spp., M. tuberculosis, and M. avium intracellulare when used for diagnostic testing.
    RestrictionSimultaneous ordering of any combination of direct probe, amplified probe, and/or quantification for the same organism in a single encounter is not reimbursable.
    Quantitative testingQuantitative nucleic acid testing for Mycobacterium spp., M. tuberculosis, and M. avium intracellulare is not reimbursable.
    inv-10: Nucleic acid amplification testing (NAAT) for Mycobacteria spp., M. tuberculosis, and M. avium complex — updated NAAT-specific definition added in recent update.
    Definition updateQualitative nucleic acid amplification testing (NAAT) for Mycobacteria spp., M. tuberculosis, and M. avium complex was added to reimbursable tests.
    Terminology changeReferences to vendor-specific tests (eg, Hologic Amplified MTD) were replaced with the term 'NAAT' for clarity.
    Organism namingNaming updated from 'M. avium intracellulare' to 'M. avium complex' to align with current conventions.
    inv-11: Earlier molecular direct probe methods (now removed/not available) — note about removal/deprecation of direct probe testing.
    DescriptionDirect probe testing (earlier molecular methods) was removed because it is no longer available.
    Policy effectThe prior policy references to direct probe methods and certain codes were removed and replaced with NAAT terminology.
    Coding notePolicy Update History documents removal of direct-probe–related codes and addition of NAAT-related codes in recent updates.